4[7]Ceriello A, Quatraro A, Giugliano D. New insights on nonenzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med, 1992,9 (3): 297.
5[8]Maiello M, Boeri D, Podesta F, et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose.Diabetes, 1992,41(8) :1009.
6[9]Shimomura I, Funahashi T, Takahashi M, et al. Enhancedexpression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med, 1996,2(7):800.
4Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria, cardiovascular riskfactors and cardiovascular morbidity in a British population: the EPIC - Norfolk population - based study. Eur J Cardiovasc Prev Rehabil,2004,11 (3) :207 - 213.
5Shestakov MV, larek - Martynova IR, Kukharenko SS, et al. Cardiorenal pathology in diabetes mellitus type 1 : mechanisms of development and medical correction. Ter Arkh, 2005,77 (6) : 40 - 45.
6Schalkwijk C G, Stehouwer C D. Vascular complications in diabetes mellitus: the role of endothelial dysfunction [ J ]. Clin sci, 2005,109 ( 2 ) : 143 - 159.
